Triggering of TRAIL-R1 and TRAIL-R2 death receptors by their selective fully human agonistic antibodies induces apoptosis in primary and cultured lymphoma cells

被引：0
|
作者：
Georgakis, G
Li, Y
Humphreys, R
Andreeff, M
O'Brien, S
Younes, M
Carbone, A
Albert, V
Younes, A
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Human Genome Sci, Rockville, MD USA
[3] Baylor Coll Med, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [41] Rituximab sensitizes TRAIL-resistant B-NHL lines to apoptosis by both TRAIL and fully humanized antibodies targeting TRAIL-RI (mapatumumab) and TRAIL-R2 (lexatumumab)
    Vega, Mario I.
    Haerta-Yepez, Sara
    Baritaki, Stavroula
    Martinez-Paniagua, Melisa A.
    Gonzalez-Bonilla, Cesar R.
    Bonavida, Benjamin
    BLOOD, 2007, 110 (11) : 695A - 695A
  • [42] Tacrolimus(FK506) Induced Cytotoxicity via TRAIL-R1(DR4) or TRAIL-R2(DR5) in Jurkat T Cells
    Chung, S. Y.
    Choi, S. J. N.
    TRANSPLANTATION, 2012, 94 (10) : 1115 - 1115
  • [43] Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
    Mom, Constantijne H.
    Verweij, Jaap
    Oldenhuis, Corina N. A. M.
    Gietema, Jourik A.
    Fox, Norma Lynn
    Miceli, Rene
    Eskens, Ferry A. L. M.
    Loos, Walter J.
    de Vries, Elisabeth G. E.
    Sleijfer, Stefan
    CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5584 - 5590
  • [44] The selective targeting of myeloid-derived suppressor cells in cancer patients using an agonistic TRAIL-R2 antibody
    Dominguez, George A.
    Condamine, Thomas
    Mony, Sridevi
    Hashimoto, Ayumi
    Wang, Fang
    Liu, Qin
    Forero, Andres
    Bendell, Johanna C.
    Witt, Robert
    Hockstein, Neil
    Kumar, Prasanna
    Gabrilovich, Dmitry I.
    CANCER RESEARCH, 2017, 77
  • [45] Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis
    Yoshida, Tatsushi
    Shiraishi, Takumi
    Horinaka, Mano
    Nakata, Susumu
    Yasuda, Takashi
    Goda, Ahmed E.
    Wakada, Miki
    Mizutani, Yoichi
    Miki, Tsuneharu
    Nishikawa, Akiyoshi
    Sakai, Toshiyuki
    CANCER SCIENCE, 2007, 98 (09) : 1417 - 1423
  • [46] Tacrolimus(FK506) Induced Cytotoxicity Via TRAIL-R1 (DR4) or TRAIL-R2 (DR5) in Jurkat Cells.
    Choi, S.
    Chung, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 284 - 284
  • [47] Tacrolimus(FK506) Induced Cytotoxicity via TRAIL-R1 (DR4) or TRAIL-R2 (DR5) in Jurkat Cells.
    Choi, Soo Jin Na
    Chung, Sang Young
    LIVER TRANSPLANTATION, 2014, 20 : S158 - S158
  • [48] Tacrolimus(FK506) Induced Cytotoxicity Via TRAIL-R1 (DR4) or TRAIL-R2 (DR5) in Jurkat Cells.
    Choi, Soo Jin Na
    Chung, Sang Young
    LIVER TRANSPLANTATION, 2012, 18 : S148 - S148
  • [49] The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation
    Mühlenbeck, F
    Schneider, P
    Bodmer, JL
    Schwenzer, R
    Hauser, A
    Schubert, G
    Scheurich, P
    Moosmayer, D
    Tschopp, J
    Wajant, H
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (41) : 32208 - 32213
  • [50] Absence of gene mutation in TRAIL receptor I (TRAIL-R1)and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia
    Liu, LG
    Tanaka, H
    Ito, K
    Ito, T
    Sultana, TA
    Kyo, T
    Kimura, A
    ACTA HAEMATOLOGICA, 2005, 113 (02) : 113 - 123
12345